The generation of diradylglycerol (DRG) and phosphatidic acid (PdtOH) was investigated in neutrophils primed with granulocyte-macrophage colony-stimulating factor (GM-CSF) . Mass accumulation of DRG and PdtOH was measured using reversed-phase high performance liquid chromatography and thin layer chromatography, respectively. GM-CSF had no direct effect on the levels of PdtOH and DRG, but it increased PdtOH generation and the late phase of DRG accumulation in human neutrophils stimulated with FMLP. The elevation of the mass of PdtOH peaked -100 s and clearly preceded that of DRG, which peaked at 150 s. The diacylglycerol kinase inhibitor R59022 enhanced the sustained increase in DRG but did not produce a parallel inhibition in PdtOH production . GM-CSF was without effect on the level of inositol 1,4,5-triphosphate [Ins(1,4,5)P3] and did not affect the liberation of Ins(1,4,5)P3 induced by FMLP. These findings exclude the involvement of the PtdIns(4,5)PZ-specific phospholipase C/diacylglycerol pathway in the sustained phase of DRG accumulation. The early (30-s) appearance ofPdtOH clearly suggests that GM-CSF enhanced FMLP receptor-linked phospholipase D (PLD) generation of PdtOH. PLD was assessed more directly by formation of labeled phosphatidylethanol (PEt) through PLD capacity of catalyzing a trans-phosphatidylation in presence ofethanol. The formation ofPEt associated with a concomitant decrease in PdtOH directly demonstrated that the mechanism by which GM-CSF enhances PdtOH production is activation of a PLD active on phosphatidylcholine. This study provides evidence that the mechanism ofaction ofGM-CSF involves upregulation of PLD activity leading to enhanced generation of PdtOH and DRG in FMLP-stimulated neutrophils. These findings may provide the basis for several of the priming effects of GM-CSF.
pathway (9, 10). GM-CSF also augments neutrophil phagocytosis (11) and the concomitant synthesis of LTB 4 (12) .
Although high affinity binding sites for GM-CSF have been demonstrated (13) , little is known about the signal transduction pathway(s) involved in the actions ofGM-CSF. A growing body of evidence implicates guanine nucleotide regulatory proteins in coupling receptor occupancy to the activation of the phospholipase C (PLC) pathway in neutrophils (14, 15) . PLC activation produces two putative second messengers, inositol 1,4,5-trisphosphate [Ins(1,4,5)P3], which releases Cat+ from intracellular stores, and diglycerides, which act as endogenous activators of protein kinase C (PKC) (16) . Recent data demonstrated the involvement of guanine binding proteins in neutrophil activation and priming by GM-CSF (7, 17), as well as tyrosine phosphorylation ofproteins, including the ras gene product P21 (2), a GTP binding protein . However, more recent reports dissociated the mechanism of action ofGM-CSF from direct stimulation ofthe phosphatidylinositol 4,5-bisphosphate [Ptdlns(4,5)P2] hydrolysis pathway and PKC activation (18, 19) . On the other hand, it has been suggested that GM-CSF may act through the modulation of the generation of cyclic nucleotides (19) .
Another potential signaling pathway in cell activation involving a phospholipase D (PLD) has recently been studied in various cell types, including human phagocytes and the HIr60 human promyelocytic cell line (20) (21) (22) . The activation of PLD may involve a guanine nucleotide binding protein (23) . It gives rise to choline-linked phosphoglycerides breakdown products, namely choline and phosphatidic acid (PdtOH), with diacyl-PdtOH and 1-0-alkyl-2-acyl-PdtOH species (21, 22) . PLD activation also leads to the formation of the corresponding diradylglycerides (DRG) through a phosphatidate phosphohydrolase activity (24) .
To gain insight into the mechanisms whereby GM-CSF enhances neutrophil functional responsiveness, we have studied its effects on the phospholipase pathway(s) involved in neutrophil activation. Our findings indicate that pretreatment of the cells with GM-CSF leads to enhanced accumulation of PdtOH and DRG upon simulation with FMLP, and strongly suggest that this effect is mediated by an upregulation of PLD activity.
Materials and Methods
Reagents. FMLP, 4-dimethylaminopyridine, triethylamine, PLD (Cabbage type I), phosphatidylcholine (dioleoyl), phosphatidic acid dipalmitoyl, 1,3-distearoyl-glycerol (1,3-distearin), 1,2-distearoylrac-glycerol, 1,2-dipalmitoyl-sn-glycerol, 1.2-dioleoyl-sn-glycerol, 1-stearoyl-2-arachidonoyl-sn-glycerol, and coomassie brilliant blue (CBB R-250) were purchased from Sigma Chemical Co. (St . Louis, MO). 1,2-dilinoleoyl-rac-glycerol was from Nu Check Prep Inc., (Elysian, MN) . 1-0-hexadecyl-2-oleoyl-and 1-0-hexadecyl-2-palmitoyl-sn-glycerol were prepared by PLC (type XIII; Sigma Chemical Co.) digestion of the corresponding phosphatidylcholines (Sigma Chemical Co.). 1-0-[3H]alkyl-2-acetyl-sn-glycero-3-phosphocholine (132-179 Ci/mmol) was purchased from Amersham Corp. (Arlington Heights, IL) . a-naphthyl-isocyanate and 1,8-diazacyclo- [5, 4 ,0]-undec-7-ene were from Aldrich Chemical Co. (Milwaukee, WI) . Dimethylformamide was from Pierce Chemical 768 Co. (Rockford, IL) . Silica gel 60 thin layer chromatography (TLC) plates were from Merck & Co. (Darmstadt, FRG). R59022 was bought from Janssen Life Sciences (NJ). HBSS was from Gibco Laboratories (Burlington, Ontario), and all solvents were HPLC grade from Anachemia (Montr6al, Qu6bec) . Biosynthetic human recombinant GM-CSF (The Genetics Institute, Cambridge, MA) was resuspended in sterilebuffered saline containing 0.01% human serum albumin (HSA); its stock solution (at 100 nM) was stored at -20°C and handled aseptically.
Neutrophil Preparation. Neutrophil suspensions were prepared as previously described (25) . Briefly, venous blood collected on citrate dextrose phosphate adenine anticoagulant solution from healthy volunteers was centrifuged (250 g, 10 min), and the platelet-rich plasma was discarded . After dextran sedimentation, PMN were obtainedby centrifugation over a Ficoll-Paque cushion . Contaminating erythrocytes were removed by hypotonic lysis, and purified neutrophils (98% neutrophils) were finally resuspended in HBSS containing 10 mM Hepes and 1.6 mM Cal*, pH 7.4. Cells were counted (model ZM; Coulter Electronics Inc., Hialeah, FL) and diluted in HBSS to a final concentration of 2 x 10'/ml. Cell viability, as determined by trypan blue dye exclusion, was always >96% at the end of each experiment.
Incubation Conditions. Neutrophils (2 x 10'/ml) were preincubated at room temperature (RT; 20°C) for the desired period of time with or without 400 pM GM-CSF (a concentration ofGM-CSF previously described to induce optimal priming effects on neutrophil functions ; see references 8 and 12) . The cell suspensions were then warmed to 37°C for 5 min before FMLP challenge. At selected times after the addition ofFMLP, the reactions were stopped by vortexing 4-ml aliquots of neutrophil suspensions with 7.2 ml of ice-cold chloroform/methanol/HCI (10 N) (100:200:2; vol/ vol/vol). Control experiments used unstimulated neutrophils preincubated with or without GM-CSF. In the experiments with the DRG kinase inhibitor R59022, neutrophils were preincubated 10 min at 37°C with 20 p.M R59022 before the addition of FMLP, as described (26) .
Sample Preparation for DRG and PdtOH Analysis. Lipids were extracted by the Bligh and Dyer's technique (27) , with modification . Briefly, after vortexing the cell suspension with cold chloroform/methanol/HCI (10 N) (as described above), samples were mixed with chloroform (0.6 ml/ml of the original cell solution) containing 1 lAg of 1,3-distearin as an internal standard. After centrifugation (750 g, 10 min at 4°C), the chloroform layer was carefully removed, and the aqueous layer was vortexed with 2 ml chloroform . The combined chloroform fractions were washed with 1 ml of 0.1 N HCI and dried under nitrogen . The lipid samples were then dissolved in chloroform/methanol (1:2; vol/vol).
TLC ofLipids. Separation of the different neutral lipids was achieved using silica gel-60 plates previously developed in chloroform/methanol (1:2; vol/vol) for cleaning purposes. The elution solvent was made up ofbenzene/chloroform/methanol (80:15:3.25 ; vol/vol/vol) (system I). After evaporation of organic solvents under nitrogen, the plates were slightly stained with coomassie brilliant blue. Theplates were then dried, the areas containing the diglyceride subclasses were scraped off, and the silica gel was collected . The DRG were eluted from the silica gel with 8 ml hexane/ether (25 :75 ; vol/vol). The samples were dried under nitrogen, and the DRG were either converted to their naphthylurethane derivatives for subsequent separation and quantitation by HPLC (see below) or to their anthracene-propionyl derivatives for further analysis by mass spectrometry (see below) .
PdtOH were resolved from other lipids by TLC on silica gel-60 using a solvent containing chloroform/pyridine/88% formic acid (50:30:7 ; vol/vol/vol) (system II). In some experiments, after an initial development of the TLC plate in system I, the phospholipids that remain at the origin were scraped offand recovered from the silica gel by sequential elution with 5 ml chloroform/MeOH (1 :2; vol/vol) and 2 ml McOH, and separated using solvent system II to resolve PdtOH.
Analysis ofDRG: HPLC Separation and Quandtadon ofDRG. DRG samples purified by TLC with solvent system I and recovered from TLC plates were prepared for analysis using a slight modification of Rustow's method to obtain naphthylurethane derivatives (28) . Briefly, dried DRG samples were dissolved in 100 pl dimethylformamide (DMF). 5 Pl of a-naphthylisocyanate (a large excess of the reagent) and 10 pl of 1,8-diazacyclo- [5, 4 ,0]-undec-7-ene (0.1 M solution in DMF) were added simultaneously to each sample. The stoppered glass vials were heated at 85°C under nitrogen for 30 min. After cooling to RT, excess reagent was destroyed by addition of 500 14 of McOH for 10 min, and the reaction mixture was then centrifuged (250 g, 5 min at RT). The clear supernatant was carefully removed, and the precipitated material was then resuspended in 0.6 ml ether and centrifuged at 250 g . The clear supernatants were combined and mixed with 10 ml of solvent A (acetonitrile/water, 75:25; vol/vol) and applied to Sep Pak Cis cartridges (Waters Associates, Milford, MA) prewashed with 15 ml solvent A. The samples were then washed with 5 ml solvent A, followed by 10 ml acetonitrile/water (90:10), and the derivatized DRG were eluted with 5 ml of distilled n-hexane . The derivatized DRG samples were dried and dissolved in isopropanol for HPLC analysis. Sep Pak cartridges were then washed with 4 ml isopropanol and reequilibrated with solvent A for further use. Separation and quantitation of neutrophil DRG was achieved using a Radial Pak Cs cartridge (5 x 100 mm, 10-um particles; Waters Associates) protected by a Cs guard cartridge (Pierce Chemical Co.) . Derivatized DRG were eluted at a flow rate of 1.5 ml/min using two solvent mixtures : solvent A-1, acetonitrile/water (70:30; vol/vol) and solvent A-2 (100% acetonitrile), and the following program: step 1, 0-5 min, isocratic in A-1; step 2, 5-5.5 min, 100% A-1 to 33% A-1/67% A-2; step 3, 5.5-11.5 min isocratic in 33% A-I/ 67% A-2; step 4, 11 .5-13 min from 33% A-1/67%D A2 to 5% A-1/95% A-2; step 5, 13-16 min, isocratic in 5% A-1/95% A-2; step 6, 16-16.1 min from 5% A-1/95% A-2 to 100% A-2; step 7, 16 .1-26 min, isocratic in 100% A-2; step 8, 26-26.1 min from 100%D A-2 to 100% A-1; step 9, 26 .1-36.5 min isocratic in 100% A1 . DRG species were detected by absorbance at 223 nm using a variable wavelength UV photometer. The products were identified on the basis of their coelution with authentic standards. Quantitation of DRG was performed by comparison of the peak areas with that of the internal standard 1,3-distearin; quantitative values given for DRG are the sum of all DRG species appearing on the HPLC tracings. Those conditions of analysis using UV detection at 223 nm allowed a detection limit of 5-10 pmol DRG.
Analysis ofPWOH. Samples prepared for PdtOH analysis (using TLC with solvent system II, see above) were stained with coomassie brilliant blue, as described by Nakamura and Handa (29) . Briefly, TLC plates were immersed in a 0.03% solution of the dye in 30% McOH containing 100 mM NaCl, for 30 min, and destained for 5 min in 30% McOH, 100 mM NaCl . The plates were air dried and scanned using an image analysis system (Amersham Corp.) . Integration of thin layer bands was performed using GIA000 software supplied with the image analyzer (Amersham Corp.) . Quantitation of PdtOH was achieved using a standard curve (0 .75, 1.5, and 314g) dipalmitoyl phosphatidate obtained for each analysis. In some experiments, the fatty acid composition of TLC-purified PdtOH was studiedby GC-MS using the procedure described above 76 9
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for DRG species. Alkyl-PdtOH were assessed as alkyl-lyso-PdtOH after alkaline hydrolysis of TLC-purified PdtOH species. Briefly, PdtOH were hydrolyzed with 80% methanolic NaOH (1 N) overnight at RT, and the base hydrolysis products were extracted using the Bligh and Dyer's technique (27) . The organic phase was then dried and analyzed on silica gel using solvent system II . Lyso-alkylPdtOH were quantitated using charring densitometry (30) andlysoPdtOH for standard curve. Preparation ofPhosphatidylethanol (PEt). PEt was prepared from phosphatidylcholine (dioleoyl) by trans-phosphatidylation with cabbage PLD. Cabbage PLD (50 U) dissolved in 1 ml of 10% ethanol, 40 mM calcium chloride, pH 5.6, and 400 wg of phosphatidylcholine dissolved in 1 ml of water-saturated diethylether were incubated overnight at RT. The lipids were extracted with diethylether/ethanol (4 :1; vol/vol), and the organic phase was dried under nitrogen before being separated by TLC on silica gel-60 plates in chloroform/methanol/acetic acid (65:15:2; vol/vol/vol) (21) . PEt was localized by coomassie brilliant blue staining (29) and identified by comparison to published Rf values (21) .
PEt Biosynthesis in Neutrophils. Neutrophils (10) were prelabeled with 1-0-['H]alkyl-2-acetyl-sn-glycero-3-phosphocholine . 1-0-['H]alkyl-2-acetyl-sn-glycero-3-phosphocholine (10 PCi/ml, in HBSS containing 2.5 mg HSA was added to the cell suspension at the final concentration of 15 nM (2 uCi/ml), and the cells were incubated at 37°C for 90 min. Cells were washed twice in HBSS buffer containing 0.5 mg/ml HSA and resuspended in the same buffer (without HSA) to a final concentration of 10'/ml . Cells were treated with 400 pM GM-CSF or diluent, as described above. The cell suspensions were then warmed to 37°C for 5 min before FMLP challenge in the absence or presence of 0.5% ethanol added 1 min before the agonist. Lipids were extracted as described above and the lipids were resolved by TLC on silica gel-60 plates as before. Standard lipids were located by coomassie brilliant blue staining and plates were scraped in 5-mm slices and assayed for radioactivity.
Inositol 1,4,STrisphosphate (Ins(1,4,5)P3) Measurement by RIA. Ins-(1,4,5)P3 was assayed in incubation media with a commercial RIA kit (Amersham Corp.) . Briefly, neutrophils (10'/ml) were preincubated for 1 h at 37°C with or without 400 pM GM-CSF before stimulation with 1 pM FMLP. Incubations were terminated by addition of 1 vol ice-cold TCA (15%). After sedimentation of precipitated material, supernatants were extracted with 10 vol of water-saturated diethyl ether and then titrated to pH 7.5 with NaHC03. tants were assessed using Amersham Corp.'s specified assay procedures. Statistical Analysis. Results are expressed as the mean ± SEM of at least five experiments. Statistical analysis was performed by student's paired t test, and significance was considered attained when p was <0.05, one-tailed.
Results
Influence of GM-CSF on DRG Levels in Human Neutrophils. Separation and quantitation of human neutrophils DRG were performed using a sensitive HPLC-UV method that did not require radiolabeling. Standards of various DRG species were separated as naphthylurethane derivatives by HPLC (Fig. 1) . The elution times of DRG naphthylurethane derivative standards were dependent on the degree of fatty acid unsaturation and carbon chain length . The 1,2-diaryl (C18:2/C18 :2 derivative eluted first (Fig. 1, peak A) and was followed by 1,2-diaryl C18:0/C20 :4 (peak B), 1,2-diaryl 1-0-alkyl-2-aryl C16:o/C1aa (peak E), 1,2-diaryl C18 :0/C18 :0 (peak F), and 1,3-diaryl C1a:o/C18 :o (peak G). Using this HPLC system, naphthylurethane derivatives ofDRG obtained from neutrophils eluted between 17 and 25 min of the 36.5-min elution program (Fig. 2) . The limit ofdetection for DRG naphthylurethanes, as assessed with 1,2-dioleoylglycerol at 223 nm, was 5-10 pmol. The identification ofpeaks in biological sample chromatograms was made by comparison of retention times with those of DRG standards . We used 1,3-distearin as an internal standard to monitor DRG recovery throughout the extraction procedures and conversion into naphthylurethane derivatives. The 1,3-distearin naphthylurethane standard eluted as two peaks (Fig. 1 , peaks F and G; Fig. 2, peaks 8 and  9 ). In fact, TLC analysis of the commercial 1,3-distearin standard revealed the presence ofthe 1,2-distearin isomer, which eluted as peak F ofFig . 1 in HPLC analysis . In contrast, we did not observe the presence of 1,3-DRG isomers in TLC analysis ofbiological DRG samples . Recovery of the internal standard at the level ofHPLC analysis was found to be 30-50%.
Priming Effects of Granulocyte-Macrophage Colony-Stimulating Factor HPLC analysis ofDRG species also showed some qualitative limitations; for example, compounds C18:0/C20 :4 ( Fig. 1, showed similar levels of DRG (sum of all species detected), e.g., 167 ± 36 and 159 ± 29 pmol/101 neutrophils, respectively (n = 5), as assessed by HPLC analysis and correction for recovery using the internal standard . Similarly, we did not detect changes in the basal levels of DRG upon incubation of the cells with GM-CSF, over a 30-min period at 37°C' (data not shown) . These data indicated that GM-CSF did not induce by itself the formation of DRG. Fig. 3 shows the kinetics of the changes in DRG levels in FMLP-stimulated neutrophils. When neutrophils were stimulated with 1 AM FMLP, the levels of DRG rapidly increased by 45% within 30 s (p < 0.05), then dropped back to basal levels by 2.5 min . This was followed by a slower rise of DRG at 5 min (final level, 141% of basal) . Neutrophils treated with GM-CSF exhibited two phases of DRG accumulation when challenged with FMLP (Fig. 3) . The most striking effect of GM-CSF pretreatment was a second phase of DRG accumulation, which was maximal at 2.5 min before dropping back to basal levels by 5 min (Figs. 2 D and  3) . The mean change (percent ofcontrol) of that second peak was 208 ± 26% (p < 0.05), ranging from 135 to 293%. The first peak ofDRG accumulation in GM-CSF-treated neutrophils stimulated with FMLP reached 153% (p < 0.05) of the basal DRG levels. While there was no difference in the level ofthe first peak (30 s) ofDRG accumulation in control or GM-CSF-treated cells, the levels of DRG at 2.5 min were significantly elevated in cells pre-exposed to the growth factor as compared with control cells. Influence ofGM-CSF on the Levels ofPdtOH in Human Neutrophils. The stimulation of neutrophils by FMLP led to a slight but nonsignificant increase ofthe level of PdtOH within 1 min 45 s (Fig. 5) . GM-CSF, by itself, did not affect the basal levels of PdtOH in unstimulated neutrophils (data not shown) . However, the addition ofFMLP to GM-CSF-treated neutrophils resulted in a rapid and significant increase of the levels of PdtOH, which was detectable as early as 30 s and remained stable for up to 5 min (Fig. 5 ). Under these conditions, PdtOH increased from 0.24 ± 0.07 Fig to 0 .99 ± 0.15 To calculate changes in diglyceride subspecies, an arbitrary unit of 1 was given to each subspecies (control at 0 min) . Data represent the mean ± SEM of five experiments . " p < 0.05 . wg/10 7 neutrophils at 1 min 45 s. At each time studied after FMLP challenge, the levels of PdtOH in GM-CSF-treated neutrophils were consistently two-to threefold higher than those of cells that had prior stimulation with FMLP (t = 0 min; Fig. 5 ).
Preincubation of GM-CSF-treated neutrophils with R59022, a DRG kinase inhibitor, was associated with a significant enhancement ofboth phases of FMLP-induced accumulation of DRG (Fig. 6) . In contrast, preincubation of neutrophils with 20 j,M R59022 did not significantly alter the time course ofaccumulation of PdtOH in GM-CSF-treated neutrophils stimulated with FMLP (Fig. 7) . Basal levels of DRG and PdtOH in unstimulated neutrophils pretreated with GM-CSF were unchanged by preincubation of cells with R59022 . Taken together, these observations are consistent with a major contribution of a PLD in the generation of PdtOH induced by GM-CSF treatment .
The alkyl-acyl composition of PdtOH was studied after basic hydrolysis under mild conditions (80% methanolic 1 N NaOH; 15 h at RT) . The resulting products were extracted and purified by TLC. The levels of alkyl-PdtOH were not detectable in control cells nor in unstimulated cells treated with GM-CSF using charring densitometry (results not shown) . However, when GM-CSF-treated neutrophils were stimulated with FMLP, alkyl-PdtOH rapidly increased to a detectable level and reached a plateau (0.06 ,ug/107 neutrophils) corresponding to 5-10% of the total PdtOH content within 60 s (Fig. 8) . However, since recovery of a standard was not included, the values may underestimate the amount of alkyl-PdtOH .
Effect of GM-CSF on PEt Formation in Human Neutrophils. Advantage was taken of property of PLD-catalyzed formation of PEt by transphosphatidylation reaction in the presence of ethanol to assess the effect ofGM-CSF on PLD activity. When 1-0-[3H]alkyl-2-acetyl-sn-glycero-3-phosphocholine was added for 90 min to human neutrophils, 85 ± 2% was taken up by the cells . 88 ± 2% (n -3) of the total cell radioactivity was in alkyl-acyl-phosphatidylcholine. Stimulation of these prelabeled neutrophils with FMLP led to a production of (Fig. 9 ). These data demonstrate that GM-CSF up- Human neutrophils were labeled with 1-0-[3H]alkyl-2-acetyl-snglycero-3-phosphocholine, as described in Materials and Methods . Cells (107/ml) were pretreated with or without GM-CSF (400 pM) for 1 h at RT before stimulation with 1 AM FMLP at 37°C in the presence or absence of 0.5% ethanol . Lipids were extracted and separated by TLC, and standard lipids were located by coomassie brilliant blue staining. Plates were scraped in 5-mm slices and assayed for radioactivity. Shown is a single experiment representative of three different ones.
regulates a phosphatidylcholine-specific PLD under these conditions. Analysis ofDRG Species in Neutrophib. Besides providing a mean for quantitation of DRG, HPLC also enabled comparison ofthe various DRG species formed under the different experimental conditions tested. HPLC analysis of the DRG in control neutrophils showed four principal DRG peaks (Fig.  2 A ; peaks 4, S, 6, and 7). Peak 4 coeluted with C18 :o/C2o :4 and C16 :0/C16 :o AAG standards (Fig. 1, peak B) . Peaks 5, 6 , and 7 comigrated with diacyl C18a/C1m, 1-0-alkyl-2-acyl C16 :0/Ct6 :o, and 1-0-alkyl-2-acy1 C16 :o/C18 :1 DRG standards, respectively (Fig. 1, peaks C, D, and E) . The DRG species eluting as peaks 2 and 3 have not yet been identified. Peak 1 had a retention time identical to that of C18:2/C18:2 ( Fig.  1, peak A) . The profile of DRG species in neutrophils was unchanged by preincubation with GM-CSF (Fig. 2 C) . Similarly, we did not detect significant changes in the profile of DRG after a 2.5-min stimulation with FMLP (Fig. 2 B) . In contrast, cells treated with GM-CSF exhibited major changes in several DRG species after 2.5-min stimulation with FMLP, with a significant increase of peaks 1, ,3, and 4 ( Fig. 2 D) .
Peak 4 showed the highest enhancement, averaging 307 ± 89% (n = 5) of its basal level . Peak 1, which eluted just after a contaminant, was detected only in GM-CSF-pretreated neutrophils stimulated with FMLP. As function of time, changes in DRG levels were due to a major contribution of peaks 1, 3, and 4.
Discussion
In the present study, we investigated the effects of GM-CSF on DRG and PdtOH levels in resting and stimulated neutrophils . It is important to point out that the present investigation relied on mass measurements, in contrast to previous studies on DRG and PdtOH in human neutrophils, which were carried out with cells prelabeled with radioisotopes (22, 31) . It is indeed uncertain that true isotopic equilibrium of membrane lipids was reached by the short periods ofradiolabeling used in those studies (32) . Therefore, it seems that direct mass measurement is likely to provide a more reliable determination of the changes in lipid species.
We demonstrated herein that in human neutrophils pretreated with GM-CSF, the chemotactic peptide FMLP induced a rapid accumulation of PdtOH, and secondarily of DRG. GM-CSF treatment had no direct effect on the levels of DRG, PdtOH, and Ins(1,4,5)P3 in unstimulated neutrophils, and affected neither the FMLP-stimulated formation of Ins(1,4,5)P3 nor the initial peak of DRG accumulation .
Activation of neutrophils by chemoattractants is dependent upon GTP-binding proteins coupled to a PLC specific for Ptdlns(4,5,)P2 (33) . Hydrolysis of Ptdlns(4,5)P2 leads to a transient rise in Ins(1,4,5)P3 and a biphasic increase in diacylglycerol (34) (35) (36) . The second phase of DRG increase observed in cytochalasin B-pretreated neutrophils stimulated with FMLP is correlated with optimal activation of the respiratory burst (35) , and unlike the initial increase, was apparently derived from a phospholipid other than PtdIns (4,5)P2 (36) . Our findings clearly ruled out a PtdIns(4,5)P2-specific PLC/diacylglycerol pathway in the mechanism ofGM-CSF action, since the concomitant early peaks in Ins(1,4,5)P3 and DRG were not altered by the cytokine in FMLP-stimulated neutrophils. Using [3H]inositol-labeled neutrophils, Coffey et al. (19) reported similar results. Several lines of evidence also dissociate the late increase in DRG from the PtdIns (4,5)P2-specific PLC pathway in cells treated with GM-CSF, and it has been suggested that DRG can be generated by PLC hydrolysis of a phospholipid other than Ptdlns(4,5)P2 or by another pathway (22, 31) . Indeed, both PMA and dioctanoylglycerol induced the accumulation of DRG (1-0-alkyl-2-acylglycerol [EAG] and 1-2-diacylglycerol [AAG]) in human neutrophils without phosphoinositide hydrolysis and calcium mobilization (36) (37) (38) (39) . In several cell types, the PMA stimulated release ofDRG and choline metabolites was consistent with the PLC-mediated hydrolysis ofphosphatidylcholine (40, 41) . Recent evidence has implicated a PLD in the formation of PdtOH in chemoattractant-stimulated H1s60 cells and neutrophils (20) (21) (22) 31) . Stimulation of 1-0-alkyl-[32P]-PClabeled cells with FMLP or PMA was found to induce the generation of alkyl-PdtOH from alkyl-phosphatidylcholine, most likely through a PLD activity (21) . In addition, the recent demonstration of DRG formation with concomitant phosphorylcholine turnover in human PMN is consistent with an activation of a PLD activity (42) .
In GM-CSF-treated cells stimulated with FMLP, a threefold increase in PdtOH preceded the twofold increase in DRG (Figs . 2, 3, and 5 ) . Under these conditions, the mass of PdtOH 77 4 was consistently four-to fivefold higher than the mass of DRG. Although PdtOH accumulation preceded the sustained phase ofDRG formation in GM-CSF-treated neutrophils challenged with FMLP, it remains possible that PdtOH could be derived from a rapid phosphorylation of the DRG pool. If so, PdtOH accumulation should havebeen inhibited by the DRG kinase inhibitor R59022 (43) . We found that R59022 increased thelate phase ofDRG accumulation, but was without significant effect on the time course of formation and accumulation of PdtOH. These observations indicated that most of the PdtOH pool is generated through the activation ofa PLD. In addition, our findings of an increased proportion of basestable PdtOH, identified as alkyl-PdtOH, in GM-CSF-treated neutrophils challenged with FMLP suggest that, since neutrophils do not contain alkyl-PtdIns(4,5)P2, a phosphatidylcholine-specific PLD might be activated under these conditions.
It has recently been suggested, on the basis of PdtOH accumulation and inhibition of AAG formation by propanolol, an inhibitor of phosphatidate phosphohydrolase, that DRG were formed by sequential action of PLD and PdtOH phosphohydrolase in FMLPstimulated neutrophils pretreated with cytochalasin B (31) . Moreover, the observed accumulation of either alkyl-PdtOH and alkyl-DRG provided additional evidence that PdtOH and DRG are generated by hydrolysis of phosphatidylcholine by a PLD (22, 31) . We have found in GM-CSF-treated neutrophils that 100 1AM propanolol increased the basal level of PdtOH from 0.109 ± 0.026 to 0.244 t 0.07 Wg/10' neutrophils . In GM-CSF-treated neutrophils stimulated with FMLP for 2.5 min, propanolol increased the levels of PdtOH from 0.388`+_ 0.054 to 0.483 ± 0.058 feg/10' cells . These efdc¬s of propanolol provide evidence for the presence of an -active phosphatidate phosphohydrolase, and indicate that part ofthe DRG accumulation its GM-CSFtreated' neutrophils stimulated with FMLP may derive from PdtOH via a phosphohydrolase. However, our results do not exclude DRG formation by a phospholipase C-mediated hydrolysis of phosphatidylcholine (40, 41) .
Stimulation by FMLP of 1-0-[3H]alkyl-2acyl-sn-glycero-3-phosphocholine-prelabeled neutrophils, led to rapid and enhanced formation of [3H]alkyl-PdtOH in GM-CSF-pretreated neutrophils. In addition, in the presence of ethanol, an increased formation of [3H]alkyl-PEt (concomitant with a decreased generation of [3H]alkyl-PdtOH) was observed in GM-CSF-pretreated neutrophils challenged with FMLP. As PLD catalyzes trans-phosphatidylation in presence ofalcohols (21), we concluded that GM-CSF upregulates a phosphatidylcholine-specific PLD in FMLP-stimulated neutrophils.
The RP-HPLC analysis of naphthylurethane derivative of neutrophil DRG, in addition to providing quantitative data, also unravelled specific alterations in the DRG profiles of neutrophils under various experimental conditions. Identification of the various DRG species, based on coelution with authentic standards is tentative and requires confirmation. Preliminary mass spectrometric analysis (data not shown) already confirmed that neutrophil DRG contain all the species detected by HPLC (and several others) and, furthermore, confirmed the major change observed in DRG species after FMLP stimulation of GM-CSF-treated neutrophils (Fig. 2) , i.e., an increase mainly in C18:o/C2o :4 AAG. Studies are currently in progress to characterize DRG and PdtOH profiles in resting and activated neutrophils . Such analysis of DRG and PdtOH species are crucial to the understanding of the regulation of the pools of precursors of bioactive lipids, such as arachidonic acid (44) (45) (46) , and of cellular responses, since AAG and EAG species have different regulatory properties on PKC activity and superoxide production (47) .
It is noteworthy that there are several similarities between the effects of.GM-CSF and the fungal metabolite cytochalasin B. We have found that neutrophil pretreatment with cytochalasin B or GM-CSF similarly enhanced the accumulation of DRG upon stimulation with FMLP (see also reference 31) , and that cytochalasin B treatment ofGM-CSF primed neutrophils did not cause a cumulative increase of DRG (data not shown) . Like GM-CSF, cytochalasin B primes neutrophils for enhanced functional responses, including degranulation (48), respiratory burst (35) , and phospholipase A2 activation (46) . Our results clearly suggest that the priming effect ofGM-CSF on the respiratory burst in FMLP-stimulated cells is due to the enhanced sustained formation of DRG in these cells and the possible subsequent activation of the PKC (49) . DRG and PdtOH, through DRG lipase (44) or specific PdtOH phospholipase A2 (45) , are both potential sources for
